{"id":"W2525487380","doi":"10.1182/blood.v120.21.2844.2844","title":"An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; International Prognostic Scoring System; Polycythemia vera; Constitutional symptoms; Internal medicine; Adverse effect; Bone marrow; Anemia; Gastroenterology; Surgery; Myelodysplastic syndromes","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008364581,0.0002463329,0.0002786424,0.0003640156,0.0005277248,0.000480275,0.0003747483,0.0004901911,0.05479549],"category_scores_gemma":[0.001657408,0.0001679306,0.0002616776,0.0003496042,0.0001605829,0.0004497111,0.0008842815,0.0007839947,0.007481746],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003392704,"about_ca_system_score_gemma":0.0008078442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000225368,"about_ca_topic_score_gemma":0.0004195135,"domain_scores_codex":[0.9996858,0.0001439599,0.00002418674,0.00005781235,0.00003693271,0.00005131797],"domain_scores_gemma":[0.9985216,0.0003820774,0.0003508456,0.0001021454,0.00007785018,0.0005655374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03057258,0.01232829,0.06695104,0.0005110051,0.0001526973,0.001603244,0.0004457124,0.001659911,0.0131034,0.001513478,0.1022184,0.7689403],"study_design_scores_gemma":[0.04392339,0.07422719,0.2573819,0.0004249185,0.0008159131,0.008281563,0.0004503649,0.01962246,0.01510593,0.002621883,0.5770243,0.0001201709],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.8580653,0.002228367,0.01307512,0.00552529,0.0002986274,0.009753214,0.005007103,0.00294217,0.1031048],"genre_scores_gemma":[0.9549322,0.0007293149,0.01115837,0.0026447,0.0006300267,0.004690442,0.003712689,0.0001613006,0.02134105],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.05479549,"threshold_uncertainty_score":0.1833092,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01388309186362673,"score_gpt":0.2724081887448032,"score_spread":0.2585250968811765,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}